Lyell Immunopharma, Inc.

LYELSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1806952

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$130.0K	$84.7M	$10.7M	$7.8M	$657.0K
Research and Development Expense	—	—	$138.7M	$182.2M	$63.6M
Operating Expenses	$247.1M	$271.7M	$225.4M	$219.7M	$102.7M
Operating Income (Loss)	-$247.0M	-$187.1M	-$214.8M	-$211.9M	-$102.1M
Nonoperating Income (Expense)	$12.4M	$3.9M	-$35.4M	$7.5M	-$27.3M
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$234.6M	-$183.1M	-$250.2M	-$204.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$490.9M	$750.0M	$937.6M	$1.1B	$908.3M
Assets, Current	$379.6M	$554.7M	$651.3M	$626.3M	$617.5M
Cash and Cash Equivalents, at Carrying Value	$145.6M	$123.6M	$293.8M	$140.4M	$96.7M
Liabilities	$108.0M	$95.1M	$104.3M	$197.6M	$189.8M
Liabilities, Current	$53.8M	$34.5M	$37.0M	$46.7M	$49.3M
Accounts Payable, Current	$5.4M	$4.8M	$3.9M	$3.2M	$9.4M
Stockholders' Equity Attributable to Parent	$833.3M	$929.8M	-$292.5M	-$111.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$163.7M	-$169.6M	-$126.2M	-$160.9M	$39.5M
Net Cash Provided by (Used in) Investing Activities	$184.0M	-$11.5M	-$121.6M	-$273.5M	-$422.4M
Net Cash Provided by (Used in) Financing Activities	$1.7M	$10.6M	$401.2M	$476.8M	$351.2M
Payments to Acquire Property, Plant, and Equipment	$2.7M	$24.3M	$65.5M	$51.5M	$16.0M
Payments for Repurchase of Common Stock	—	—	—	$11.8M	$185.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)